Keto-Mojo published a secondary analysis of two trials evaluating three dietary approaches in people with multiple sclerosis using metabolomic age as a biomarker to measure biological aging.

Globally, 537 million people live with diabetes, a number on track to reach 643 million by 2030. Insulin resistance is the root cause of many chronic diseases, driven by decades of ultra-processed food, excess sugar, and a healthcare system designed to manage symptoms, not get to the root cause. The good news? The metabolic dysfunction is preventable. While conventional medicine treats the symptom, we're building the tools to address the root problem. Founded in 2017, Keto-Mojo is a global metabolic health ecosystem built on one conviction: accurate metabolic data should be accessible to everyone. Our FDA-cleared GK+ blood glucose and ketone meter, paired with the HIPAA- and GDPR-compliant MyMojoHealth remote patient monitoring platform, puts real-time glucose, ketone, and GKI data in the hands of clinicians and patients who are ready to stop guessing and start optimizing their metabolic health. Today, we operate in 38+ countries and support 100+ clinical trials across metabolic disease, type 2 diabetes, obesity, neurological disorders, oncology, and mental health. Why clinicians choose Keto-Mojo: → Remote Patient Monitoring: Real-time biomarker data that bridges the gap between appointments. → Evidence-Based Interventions: GKI and ketone tracking that translates data into clinical practice. → Scalable, Compliant Infrastructure: Patient population management built for the demands of modern health care. → Clinical Trial Proven: Trusted infrastructure in 100+ trials across metabolic disease, neurology, oncology, and more. 📩 Every Friday, our Spotlight on Keto Research newsletter brings you the latest metabolic health research straight to your inbox. Follow along, comment, and share. Because metabolic health is a conversation worth having.